Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
Here, we present a protocol to generate a three-dimensional simplified and undifferentiated skin model using a micromachined microfluidic platform. A parallel flow approach allows the in situ deposition of a dermal compartment for the seeding of epithelial cells on top, all controlled by syringe pumps.
This work presents a new, cost-effective, and reliable microfluidic platform with the potential to generate complex multilayered tissues. As a proof of concept, a simplified and undifferentiated human skin containing a dermal (stromal) and an epidermal (epithelial) compartment has been modelled. To accomplish this, a versatile and robust, vinyl-based device divided into two chambers has been developed, overcoming some of the drawbacks present in microfluidic devices based on polydimethylsiloxane (PDMS) for biomedical applications, such as the use of expensive and specialized equipment or the absorption of small, hydrophobic molecules and proteins. Moreover, a new method based on parallel flow was developed, enabling the in situ deposition of both the dermal and epidermal compartments. The skin construct consists of a fibrin matrix containing human primary fibroblasts and a monolayer of immortalized keratinocytes seeded on top, which is subsequently maintained under dynamic culture conditions. This new microfluidic platform opens the possibility to model human skin diseases and extrapolate the method to generate other complex tissues.
Recently, advances have been made toward the development and production of in vitro human skin models for the analysis of the toxicity of cosmetic and pharmaceutical products1. Researchers in pharmaceutical and skin care industries have been using animals, mice being the most common, to test their products2,3,4,5. However, testing products on animals is not always predictive of the response in humans, which frequently leads to drug failure or adverse effects in humans and consequently to economic losses5,6. The UK was the first country that prohibited the use of animals for cosmetic testing in 1998. Later, in 2013, the EU banned the testing and approbation of cosmetics in animals (EU Cosmetics Regulation No. 1223/2009)7.
This prohibition is also being considered by other countries such as in 'The Humane Cosmetics Act' in the USA8. In addition to ethical concerns, the anatomical differences between animal and human skin make animal testing time-consuming, expensive, and often ineffective. Furthermore, the global in vitro toxicology testing market size is expected to reach USD 26.98 billion by 20259. For these reasons, there is a need to develop new methods and alternatives for those in vitro studies, such as bioengineered human skin models, that enable testing for safety and toxic effects of cosmetics and drugs without the use of animals.
There are two different kinds of commercially available, in vitro, human skin models. The first type consists of stratified epidermal equivalents containing multiple layers of differentiating keratinocytes that are seeded on different materials. Some of them have been approved by the Organization for Economic Co-operation and Development (OECD) and validated by the (European Centre for the Validation of Alternative Methods (ECVAM) for skin corrosion and irritation testing, such as EpiDerm or SkinEthic10,11,12. The second type are full-skin equivalents with a layer of differentiating human keratinocytes seeded on a three-dimensional (3D) scaffold that contains fibroblasts, such as T-Skin and EpiDerm-FT. However, these models are cultured under static conditions, which makes them unable to accurately represent human physiological conditions.
Recent interest has focused on generating in vitro 3D skin models in cell culture-insert (CCI) formats with dynamic perfusion13,14,15,16,17,18,19. However, these systems cannot be considered stricto sensu as microfluidic skin-on-chips as per their classical definition in the field. Ingber's definition for organs-on-a-chip states that the organ must be placed inside the microfluidic channels, which is a condition that only a few devices fulfil20,21. Skin-on-chips have so far modelled mostly simple epithelia as single-cell layers and/or dermal cell layers separated by a porous membrane22,23. Although there have been some advances modeling skin in microfluidic systems16,24, there is currently no literature showing an organ-on-a-chip system that fits Ingber's definition, capable of producing a multilayered skin in situ and including both epithelial and stromal components.
In this work, a new, cost-effective, robust, vinyl-based microfluidic platform for skin-on-a-chip applications is presented. This platform was produced by micro-machining, which provides more simplicity in the fabrication process, as well as increased flexibility and versatility in the layout of the device, overcoming some of the limitations of PDMS25. A way to introduce a simplified skin construct through a parallel flow controlled with syringe pumps was also designed. Parallel flow allows two fluids with very different viscosities (a buffer and fibrin pre-gel in this case) to be perfused through a channel without mixing with each other. As a proof of concept, a dermo-epidermal construct containing fibroblasts embedded in a fibrin matrix mimicking the dermis was introduced in the device, on top of which a monolayer of keratinocytes was loaded to emulate the undifferentiated epidermis. The dermal compartment height can be modulated by modifying the flow rates. The main novelty of this work, compared to previously described models22,26,27,28,29, is the development of a 3D construct inside a microchamber by means of microfluidics. Although this article presents a simplified undifferentiated skin, the long-term goal is to generate and characterize a fully differentiated skin construct to demonstrate its viability and functionality for drug and cosmetic testing purposes.
1. Chip design and micromachining parameters
Length (μm) | Width (μm) | |
Lower chamber | 28,400 | 800 |
Upper chamber | 31,000 | 800 |
Table 1: Dimensions of the upper and lower channels of the device.
Figure 1: Chip design and micromachining process. (A) Software layout showing the working space filled with both the top and bottom patterns designed for the chip. (B) Edge plotter during cutting process; cutting blade, whole vinyl sheet, and adhesive mat are shown. (C) Patterned vinyl being detached from the cut sheet. (D) Sample of an adhesive vinyl layer patterned with the top channel design. Please click here to view a larger version of this figure.
2. PDMS layer fabrication
3. Chip assembly
NOTE: For better understanding, see Figure 2.
Figure 2: Microfluidic chip assembly. (A) General scheme of the assembly of the device. Lower and upper chambers are composed of four and eleven superimposed vinyl sheets, respectively. (B) Top and lateral views of the microfluidic chip. Top and bottom channels are represented in pink and blue, respectively. (C) Image of the chip assembly using a custom-made aligner. (D) Chip image after complete assembly. Please click here to view a larger version of this figure.
4. Pump connections
NOTE: The graphical representation of pumps connections is shown in Figure 3.
Figure 3: Pump connections and inlets/outlets location. (A) Diagram showing the connection of the three different pumps to their respective inlets. Outlets connect to a waste container. (B) Chip image with labeled inlets and outlets. Abbreviations: LCi = lower chamber inlet; LCo = lower chamber outlet; UCi1 = upper chamber inlet 1; UCi2 = upper chamber inlet 2; UCo = upper chamber outlet. Please click here to view a larger version of this figure.
5. Cell culture
NOTE: The HaCaT cell line has a commercial origin. Human primary fibroblasts come from healthy donors and were obtained from the collection of biological samples of human origin registered in "Registro Nacional de Biobancos para Investigación Biomédica del Instituto de Salud Carlos III".
6. Fibrinogen pre-gel preparation
7. Parallel flow protocol
8. hKCs monolayer seeding
Figure 4: Microfluidic protocol for the generation of the dermo-epidermal construct. (A) Transverse cross-section showing the parallel flow process to generate the dermal compartment. (B) Keratinocyte monolayer seeding 24 h after dermal compartment generation. (C) Cell culture maintenance inside the microfluidic device. (D) Cross-sectional recreation of the skin inside the chip. Please click here to view a larger version of this figure.
9. Cell viability assay
NOTE: Live/Dead kit stains cells with green or red fluorescence depending on their live or dead state. For proper viability differentiation, non-fluorescent hKCs and hFBs must be used in this step. All the steps in the procedure are carried out through UCi2 with pump 2.
The designed chip is composed of two fluidic chambers separated by a 5 µm pore size PC membrane that allows the growth of the cell by allowing the passage of growth-promoting molecules from the lower chamber. The upper chamber holds the tissue construct, in this case, a monolayer of hKCs on a fibrin hydrogel containing hFBs.
The height of the channels is determined by the number of adhesive sheets added to each channel. The lower chamber is composed of 4 layers (380 µm) and the upper...
The motivation to develop this method was the desire to model skin diseases and study the effects of new and innovative therapies in a high-throughput platform. To date, this laboratory produces these dermo-epidermal equivalents by casting-either manually or with the help of the 3D bioprinting technology-the fibrin gel with fibroblasts into a cell culture insert plate and seeding the keratinocytes on top of it. Once the keratinocytes reach confluence, the 3D culture is exposed to the air-liquid interface, which induces k...
The authors declare that they have no competing financial interests.
We sincerely thank Dr. Javier Rodríguez, Dr. María Luisa López, Carlos Matellán, and Juan Francisco Rodríguez for very helpful suggestions, discussions, and/or preliminary data. We also kindly thank the contributions of Sergio Férnandez, Pedro Herreros, and Lara Stolzenburg to this project. Special thanks go to Dr. Marta García for GFP-labelled hFBs and hKCs. Finally, we recognize the excellent technical assistance of Guillermo Vizcaíno and Angélica Corral. This work was supported by the "Programa de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid", Project S2018/BAA-4480, Biopieltec-CM. This work was also supported by the "Programa de excelencia", Project EPUC3M03, CAM. CONSEJERÍA DE EDUCACIÓN E INVESTIGACIÓN.
Name | Company | Catalog Number | Comments |
Amchafibrin | Rottafarm | Tranexamic acid | |
Antibiotic/antimycotic | Thermo Scientific HyClone | ||
Calcium chloride | Sigma Aldrich | ||
Culture plates | Fisher | ||
DMEM | Invitrogen Life Technologies | ||
Double-sided tape vynil | ATP Adhesive Systems | GM 107CC, 12 µm thick | |
Edge plotter | Brother | Scanncut CM900 | |
FBS | Thermo Scientific HyClone | ||
Fibrinogen | Sigma Aldrich | Extracted from human plasma | |
Glass slide | Thermo Scientific | ||
GFP-Human dermal fibroblasts | - | Primary. Gift from Dr. Marta García | |
H2B-GFP-HaCaT cell line | ATCC | Immortalized keratinocytes. Gift from Dr. Marta García | |
Live/dead kit | Invitrogen | ||
PBS | Sigma Aldrich | ||
Polycarbonate membrane | Merk TM | 5 µm pore size | |
Polydimethylsiloxane | Dow Corning | Sylgard 184 | |
Sodium chloride | Sigma Aldrich | ||
Syringes | Terumo | 5 mL | |
Thrombin | Sigma Aldrich | 10 NIH/vial | |
Transparent adhesive vinyl | Mactac | JT 8500 CG-RT, 95 µm thick | |
Trypsin/EDTA | Sigma Aldrich | ||
Tubing | IDEX | Teflon, 1/16” OD, 0.020” ID |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone